NAD⁺ IV therapy is a drip: a bag of compounded NAD⁺ run into a vein over anywhere from ninety minutes to six hours, usually in a clinic or occasionally at home with a mobile nurse. It is the most expensive way to buy NAD⁺ by a wide margin, and it has the least evidence behind it of any format sold. Those two facts are related, and neither is a secret — they are just not on the pricing page.
What actually happens when you infuse NAD⁺
This has been measured in people exactly once, and the result is the most useful thing on this page.
Researchers ran a six-hour intravenous NAD⁺ infusion at 3 µmol per minute and sampled plasma and urine throughout. What they found was not what the marketing implies: no change in plasma NAD⁺, or in any of its measured metabolites, until after two hours. The authors describe the infused NAD⁺ as “rapidly and completely removed from the plasma for at least the first 2 h” [1]. By six hours what had appeared was increased urinary excretion of NAD⁺ itself and of methylnicotinamide.
Read that again, because it is the opposite of the mental model most people arrive with. You are not topping up a tank. For the first two hours of a drip, the measurable amount in your blood did not go up. The metabolite pattern the authors describe is consistent with the molecule being broken apart by enzymes as fast as it arrives.
That is a pilot study, and a small one. It is also the only human data on the fate of infused NAD⁺ that exists, which tells you something in itself about a therapy sold at four figures a course.
The outcome evidence, stated by people who went looking for it
In 2026 a PRISMA-guided systematic review searched the human and rodent literature from January 2010 to October 2025 and found 113 eligible studies — 33 human intervention studies, 28 of them randomized[2]. On oral precursors its conclusion is the one this site keeps arriving at: NR and NMN consistently engage the biochemical target, are generally well tolerated, and their effects on functional and metabolic outcomes are “heterogeneous and often null or endpoint-specific”.
On drips, the review says something blunter. In its own words: “No eligible outcomes trials evaluated intravenous or intramuscular NAD⁺ itself for anti-aging or wellness indications.” [2]
Not “the evidence is mixed”. Not “more research is needed”. A formal systematic review, published this year, looked for outcome trials of the thing IV clinics sell and found none to include. Every benefit you have seen attached to a NAD⁺ drip — energy, focus, recovery, slower aging, addiction — is being carried by something other than a trial of that intervention.
What it costs, and what that buys per milligram
IV is priced per session, not per month, and a course is rarely one session. Of the national in-home services we have verified, Mobile IV Medics lists $749 an infusion and The IV Doc lists $799. Against that, the injection providers we track run $93 to $249 a month, and an oral precursor is roughly $40.
One of those two makes the comparison sharper than any argument could. The IV Doc states its starting dose: 250 mg. So $799 buys 250 milligrams, which is about $3.20 a milligram. The injection sellers that publish a dose — System Labs at 1000 mg for $149, iThriveMD at 1000 mg for $249 — work out at roughly 15 to 25 cents a milligram.
That is a premium of thirteen to twenty-one times per milligram, calculated from the sellers’ own published numbers, for the format with no outcome trials. Some of that difference is real: a clinician sits with you, and delivery is genuinely different. None of it is evidence that the result is better.
The uncomfortable arithmetic is the same one that runs through this whole category, only steeper: the price ranking and the evidence ranking point in opposite directions. The drip costs the most and has no outcome trials. The capsule costs the least and has randomized human data. If you want that comparison in numbers you can check, the cost calculator does it per milligram.
“But IV is 100% bioavailable”
This is the argument every IV seller makes, and it is true in the narrow sense that nothing is lost to digestion. It is also the least relevant true thing available.
Bioavailability describes how much of a dose reaches circulation. It does not describe what happens next, and the pharmacokinetic study above is precisely a case where the two come apart: the dose reached circulation and the measurable plasma level still did not move for two hours [1]. A mechanism is a reason to run the trial. It is not a substitute for having run it — which is the recurring move in this category, and the one the injection pitch makes too.
Is it safe?
Infusion-site discomfort, flushing, nausea, chest tightness and cramping are commonly reported during NAD⁺ drips, and clinics typically manage them by slowing the rate — which is why a “six-hour” drip is six hours. What does not exist is a safety dataset comparable to the dedicated trials run on oral precursors.
There is also the regulatory point that gets left off the intake form. IV NAD⁺ sold through clinics and telehealth in the United States is compounded: not FDA-approved, and not reviewed by the FDA for safety, efficacy or quality before it reaches you. You are receiving an unapproved preparation intravenously, which is a higher- stakes route than swallowing one.
Who a drip might still make sense for
We are not going to tell you nobody should ever have one. If you have decided you want NAD⁺ administered under supervision, dislike self-injecting, and can absorb the cost without it mattering, a clinic infusion is a coherent choice made with open eyes.
What we will say is that it should not be the first thing you try. The honest order is cheapest-and-best-evidenced first: an oral precursor, then an injection if you want more, then a drip if you still want more after that. Starting at the top of the price ladder and the bottom of the evidence ladder is how this category prefers you to shop, and it is the single most expensive mistake available in it.
If you are comparing clinics rather than deciding whether to go, our IV therapy rankings cover what the sellers disclose — and the answer, mostly, is not much.